10x Genomics Announces Q3 GAAP EPS of -$0.37, Beating Expectations by $0.11

Trending News 🌧️

10x Genomics Intrinsic Value – The company’s products enable scientists to better understand the structure and function of genomes, paving the way for advances in medicine and agriculture. 10x Genomics ($NASDAQ:TXG) announced that their Q3 GAAP EPS of -$0.37 beats by $0.11.

This is good news for the company, as it indicates that their financial performance is better than expected. The company’s strong performance is due in part to their innovative products, which are helping to revolutionize genomic sequencing.

Earnings

The company had a total revenue of 497.9 million dollars and lost 142.5 million dollars in net income. Compared to the same period last year, there was a 1.5% increase in total revenue. In the last three years, 10x Genomics‘s total revenue has increased from 298.8 million dollars to 497.9 million dollars.

Price History

On Wednesday, 10X Genomics stock opened at $28.1 and closed at $26.9, down by 4.6% from last closing price of 28.2. Despite the stock dip, the company’s Q3 results were impressive, with the GAAP EPS coming in better than expected. Investors may have sold off the stock on Wednesday due to concerns about the current state of the economy and the potential impact on 10X Genomics’ business. However, the company’s strong Q3 results show that it is well-positioned to weather any economic headwinds.

VI Analysis – 10x Genomics Intrinsic Value Calculator

10X Genomics is a company that creates tools for genetic analysis. The company’s products are used by scientists to study the function of genes and to understand the cause of diseases. The company’s stock is currently trading at $26.9, which is 81% below its fair value of $142.7.

VI Peers

The company’s products include the Chromium System, an integrated solution for genome sequencing and data analysis, and the Visium Spatial Transcriptomics System, amicroarray platform for analyzing transcriptome activity in tissue samples. 10x Genomics has raised $310 million in funding from investors such as Fidelity Investments, Kleiner Perkins, and Google Ventures. 10x Genomics’ main competitors are Certara Inc, Omnicell Inc, and CardioComm Solutions Inc. These companies offer similar products and services to support genomic research.

– Certara Inc ($NASDAQ:CERT)

Certara Inc is a biopharmaceutical company that uses data and technology to improve drug development decisions. The company has a market cap of 2.49B as of 2022 and a Return on Equity of 1.81%. The company’s products and services are used by pharmaceutical, biotechnology, and medical device companies, as well as academic institutions and government agencies.

– Omnicell Inc ($NASDAQ:OMCL)

Omnicell is a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies. Their market cap of 2.49B as of 2022, and ROE of 2.67% indicates a strong and growing company. Omnicell provides solutions that help increase patient safety and improve medication adherence. Their products are used in a variety of settings, including hospitals, long-term care facilities, and retail pharmacies.

– CardioComm Solutions Inc ($TSXV:EKG)

CardioComm Solutions Inc is a medical device company that provides cardiac monitoring and arrhythmia detection solutions. It has a market cap of 2.26M as of 2022 and a return on equity of -59.73%. The company’s products are used in hospitals, clinics, and by individual patients for the remote monitoring of cardiac activity.

Summary

If you’re looking for a biotech company with promising potential, 10X Genomics could be a good option to consider. The company focuses on developing genomic analysis tools that help researchers better understand disease and develop new treatments. While 10X Genomics is not yet profitable, it has seen strong revenue growth in recent years and its products are used by some of the world’s leading research institutes. Given the potential of its technology, 10X Genomics could be a good long-term investment.